Published in Cancer Weekly, May 29th, 2007
"We're very happy to have Angiogen as a tenant at the NC Research Campus," said Higgs. "We continue to reach out and find success with exciting companies like Angiogen in the medical devices, diagnostics, health and wellness and agri-bio tech fields."
Angiogen's mission is to develop novel oncology therapies, which will benefit those suffering from cancer. The company is preparing for a Phase I trial with its lead anti-angiogenesis drug, the Angiostatic Cocktail. Prior results in a short Phase I trial and in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.